Le Lézard
Classified in: Ebola virus, Health
Subject: ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT Q3 2022


Zinzino group revenue increased with a total of 10% in Q3, compared with the previous year.

GOTHENBURG, Sweden, Oct. 5, 2022 /PRNewswire/ -- The revenue in September for Zinzino's sales markets increased by 6% and amounted to SEK 118.3 (111.6) million. Faun Pharma's external sales decreased by 5% and amounted to SEK 5.9 (6.2) million. Overall, the Group increased revenues by 5% to SEK 124.2 (117.8) million compared with the previous year.

Sales in Zinzino's sales markets increased by 10% in the third quarter of 2022 compared with the same period last year and amounted to SEK 328.8 (299.7) million. Total revenues in the Group increased by 10% in the third quarter and amounted to SEK 345.6 (313.6) million.

Accumulated revenue for January ? September 2022 increased by 4% compared with the same period last year and amounted to SEK 1009.6 (969.4) million.

Revenues were distributed as follows:

Regions, mSEK

22-Sep

21-Sep

Change

Q3 2022

Q3 2021

Change

YTD 2022

YTD 2021

Change 

The Nordics

25.7

30.0

-14 %

76.6

84.4

-9 %

232.9

271.2

-14 %

Central Europe

27.4

19.5

41 %

72.4

54.6

33 %

196.2

162.5

21 %

East Europe

29.2

29.4

-1 %

77.8

77.6

0 %

237.9

238.0

0 %

South & West Europe

15.1

12.2

24 %

39.3

32.4

21 %

114.0

102.9

11 %

The Baltics

6.7

6.3

6 %

17.8

16.6

7 %

52.5

52.2

1 %

North America

5.7

4.1

39 %

19.0

11.0

73 %

51.6

36.1

43 %

Asia-Pacific

7.2

10.1

-29 %

22.9

23.1

-1 %

57.2

59.3

-4 %

Africa

1.3

0.0


3.0

0.0


6.2

0.0


Zinzino

118.3

111.6

6 %

328.8

299.7

10 %

948.5

922.2

3 %

Faun Pharma

5.9

6.2

-5 %

16.8

13.9

21 %

61.1

47.2

29 %

Zinzino Group

124.2

117.8

5 %

345.6

313.6

10 %

1009.6

969.4

4 %


Countries in regions:

-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino, +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
[email protected]

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: [email protected]

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 14:00 the 5th of October 2022.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/zinzino/r/zinzino-ab--publ--preliminary-sales-report-q3-2022,c3643046

The following files are available for download:

https://mb.cision.com/Main/10976/3643046/1634945.pdf

2209 Pressrelease Salesreport EN


These press releases may also interest you

at 20:14
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...



News published on and distributed by: